(2021). Correction: Tisagenlecleucel infusion in patients with relapsed/refractory ALL and concurrent serious infection. BMJ Publishing Group.
Cita Chicago Style (17a ed.)Correction: Tisagenlecleucel Infusion in Patients with Relapsed/refractory ALL and Concurrent Serious Infection. BMJ Publishing Group, 2021.
Cita MLA (8a ed.)Correction: Tisagenlecleucel Infusion in Patients with Relapsed/refractory ALL and Concurrent Serious Infection. BMJ Publishing Group, 2021.
Precaución: Estas citas no son 100% exactas.